Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319955 | 1.00 | GRM2 (0.39) | GRM2GRM5GRM1SLC6A12SLC6A11 | |
| SCHEMBL6441950 | 0.80 | GRM2 (0.37) | GRM2GRM5GRM1SLC6A12SLC6A11 | |
| SCHEMBL15747165 | 0.77 | GRM2 (0.41) | GRM2GRM5GRM1SLC6A12SLC6A11 | |
| SCHEMBL23533458 | 0.76 | ALOX5 (0.45) | — | |
| SCHEMBL11693243 | 0.76 | GRM2 (0.38) | GRM2GRM5GRM1CYP1A2 | |
| SCHEMBL6152852 | 0.75 | GRM2 (0.39) | GRM2GRM5GRM1SLC6A12SLC6A11 | |
| SCHEMBL13851453 | 0.75 | GRM2 (0.39) | GRM2GRM5GRM1SLC6A12SLC6A11 | |
| SCHEMBL3321354 | 0.74 | NR1H2 (0.36) | — | |
| SCHEMBL4905394 | 0.73 | GRM2 (0.38) | GRM2GRM5GRM1SLC6A12SLC6A11 | |
| SCHEMBL18723739 | 0.73 | GRM2 (0.38) | GRM2GRM5GRM1SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066648-B1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE LABOR DR (ES) | 2017-04-12 | — | — | EP | disclosed |
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| EP-2066648-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008015266-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105680-A1 | SUBSTITUTED DIMETHYLCYCLOBUTYL COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | SIGMAR1, TMEM97, OPRK1 | GRM2 689/4885GRM5 375/4885GRM1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.